HCAT vs. DAVA, NYAX, QUBT, COUR, EVER, FSLY, BBAI, MOMO, DCBO, and BLND
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Endava (DAVA), Nayax (NYAX), Quantum Computing (QUBT), Coursera (COUR), EverQuote (EVER), Fastly (FSLY), BigBear.ai (BBAI), Hello Group (MOMO), Docebo (DCBO), and Blend Labs (BLND). These companies are all part of the "computer software" industry.
Health Catalyst vs.
Health Catalyst (NASDAQ:HCAT) and Endava (NYSE:DAVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
Health Catalyst currently has a consensus target price of $9.27, suggesting a potential upside of 101.58%. Endava has a consensus target price of $39.10, suggesting a potential upside of 88.89%. Given Health Catalyst's stronger consensus rating and higher possible upside, equities research analysts plainly believe Health Catalyst is more favorable than Endava.
Endava has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Endava, indicating that it is currently the more affordable of the two stocks.
In the previous week, Endava had 3 more articles in the media than Health Catalyst. MarketBeat recorded 9 mentions for Endava and 6 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 1.09 beat Endava's score of 0.82 indicating that Health Catalyst is being referred to more favorably in the media.
Endava has a net margin of 0.74% compared to Health Catalyst's net margin of -26.20%. Endava's return on equity of 0.89% beat Health Catalyst's return on equity.
Endava received 50 more outperform votes than Health Catalyst when rated by MarketBeat users. However, 67.63% of users gave Health Catalyst an outperform vote while only 58.36% of users gave Endava an outperform vote.
Health Catalyst has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Endava has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 62.2% of Endava shares are held by institutional investors. 2.5% of Health Catalyst shares are held by insiders. Comparatively, 18.8% of Endava shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Endava beats Health Catalyst on 12 of the 18 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
This page (NASDAQ:HCAT) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy HCAT Stock Free HCAT Stock Alerts